AustralieFrV1, PubMed, Checkpoint, bibRecord, 003254

Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study.

Identifieur interne : 003254 ( PubMed/Checkpoint ); précédent : 003253; suivant : 003255

Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study.

Auteurs : Ignace B. Vergote [Espagne] ; Antonio Jimeno ; Florence Joly ; Dionyssios Katsaros ; Corneel Coens ; Evelyn Despierre ; Christian Marth ; Marcia Hall ; Christopher B. Steer ; Nicoletta Colombo ; Anne Lesoin ; Antonio Casado ; Alexander Reinthaller ; John Green ; Martin Buck ; Isabelle Ray-Coquard ; Annamaria Ferrero ; Laure Favier ; Nick Simon Reed ; Hervé Curé ; Eric Pujade-Lauraine

Source :

Journal of clinical oncology : official journal of the American Society of Clinical Oncology [ 1527-7755 ] ; 2014.

RBID : pubmed:24366937

Descripteurs français

English descriptors

KwdEn :
- Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Disease-Free Survival, Drug Administration Schedule, Drug Eruptions (etiology), Erlotinib Hydrochloride, Europe, Fallopian Tube Neoplasms (drug therapy), Fallopian Tube Neoplasms (pathology), Female, Follow-Up Studies, Humans, Immunohistochemistry, In Situ Hybridization, Fluorescence, Kaplan-Meier Estimate, Maintenance Chemotherapy, Middle Aged, Mutation, Neoplasm Staging, Neoplasms, Glandular and Epithelial (drug therapy), Neoplasms, Glandular and Epithelial (pathology), Ovarian Neoplasms (drug therapy), Ovarian Neoplasms (pathology), Peritoneal Neoplasms (drug therapy), Peritoneal Neoplasms (pathology), Platinum Compounds (administration & dosage), Protein Kinase Inhibitors (administration & dosage), Protein Kinase Inhibitors (adverse effects), Quality of Life, Quinazolines (administration & dosage), Quinazolines (adverse effects), Receptor, Epidermal Growth Factor (genetics), Signal Transduction (genetics), Watchful Waiting.
MESH :
- chemical , administration & dosage : Platinum Compounds, Protein Kinase Inhibitors, Quinazolines.
- chemical , adverse effects : Protein Kinase Inhibitors, Quinazolines.
- chemical , genetics : Receptor, Epidermal Growth Factor.
- chemical : Erlotinib Hydrochloride.
- geographic : Europe.
- drug therapy : Fallopian Tube Neoplasms, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Peritoneal Neoplasms.
- etiology : Drug Eruptions.
- genetics : Signal Transduction.
- pathology : Fallopian Tube Neoplasms, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Peritoneal Neoplasms.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Adult, Aged, Aged, 80 and over, Disease-Free Survival, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Immunohistochemistry, In Situ Hybridization, Fluorescence, Kaplan-Meier Estimate, Maintenance Chemotherapy, Middle Aged, Mutation, Neoplasm Staging, Quality of Life, Watchful Waiting.

Abstract

This trial evaluated the efficacy of maintenance erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, after first-line chemotherapy.

DOI: 10.1200/JCO.2013.50.5669
PubMed: 24366937

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 003941
to stream PubMed, to step Curation: 003826

Links to Exploration step

pubmed:24366937

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study.</title>
<author><name sortKey="Vergote, Ignace B" sort="Vergote, Ignace B" uniqKey="Vergote I" first="Ignace B" last="Vergote">Ignace B. Vergote</name>
<affiliation wicri:level="3"><nlm:affiliation>Ignace B. Vergote and Evelyn Despierre, University Hospitals Leuven and Katholieke Universiteit Leuven, Leuven; Corneel Coens, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Antonio Jimeno, University of Colorado School of Medicine, Aurora, CO; Florence Joly, Centre François Baclesse Caen, Caen; Anne Lesoin, Centre Oscar Lambret, Lille; Isabelle Ray-Coquard, Centre Léon Bérard, Lyon; Laure Favier, Centre Georges François Leclerc, Dijon; Hervé Curé, Unicancer Institut Jean Godinot, Reims; Eric Pujade-Lauraine, Hôpital Hôtel-Dieu, Paris, France; Dionyssios Katsaros, University of Turin; Annamaria Ferrero, Ospedale Mauriziano Umberto I, Turin; Nicoletta Colombo, University of Milan-Bicocca and Istituto Europeo di Oncologia, Milan, Italy; Christian Marth, Medical University of Innsbruck, Innsbruck; Alexander Reinthaller, Medical University of Vienna, Vienna, Austria; Marcia Hall, Mount Vernon Cancer Centre, Middlesex; John Green, University of Liverpool, Liverpool; Nick Simon Reed, Gartnavel General Hospitals, Glasgow, United Kingdom; Christopher B. Steer, Border Medical Oncology, Wodonga; Martin Buck, Government of Western Australia, Department of Health, Perth, Australia; and Antonio Casado, Universitario San Carlos, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Ignace B. Vergote and Evelyn Despierre, University Hospitals Leuven and Katholieke Universiteit Leuven, Leuven; Corneel Coens, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Antonio Jimeno, University of Colorado School of Medicine, Aurora, CO; Florence Joly, Centre François Baclesse Caen, Caen; Anne Lesoin, Centre Oscar Lambret, Lille; Isabelle Ray-Coquard, Centre Léon Bérard, Lyon; Laure Favier, Centre Georges François Leclerc, Dijon; Hervé Curé, Unicancer Institut Jean Godinot, Reims; Eric Pujade-Lauraine, Hôpital Hôtel-Dieu, Paris, France; Dionyssios Katsaros, University of Turin; Annamaria Ferrero, Ospedale Mauriziano Umberto I, Turin; Nicoletta Colombo, University of Milan-Bicocca and Istituto Europeo di Oncologia, Milan, Italy; Christian Marth, Medical University of Innsbruck, Innsbruck; Alexander Reinthaller, Medical University of Vienna, Vienna, Austria; Marcia Hall, Mount Vernon Cancer Centre, Middlesex; John Green, University of Liverpool, Liverpool; Nick Simon Reed, Gartnavel General Hospitals, Glasgow, United Kingdom; Christopher B. Steer, Border Medical Oncology, Wodonga; Martin Buck, Government of Western Australia, Department of Health, Perth, Australia; and Antonio Casado, Universitario San Carlos, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jimeno, Antonio" sort="Jimeno, Antonio" uniqKey="Jimeno A" first="Antonio" last="Jimeno">Antonio Jimeno</name>
</author>
<author><name sortKey="Joly, Florence" sort="Joly, Florence" uniqKey="Joly F" first="Florence" last="Joly">Florence Joly</name>
</author>
<author><name sortKey="Katsaros, Dionyssios" sort="Katsaros, Dionyssios" uniqKey="Katsaros D" first="Dionyssios" last="Katsaros">Dionyssios Katsaros</name>
</author>
<author><name sortKey="Coens, Corneel" sort="Coens, Corneel" uniqKey="Coens C" first="Corneel" last="Coens">Corneel Coens</name>
</author>
<author><name sortKey="Despierre, Evelyn" sort="Despierre, Evelyn" uniqKey="Despierre E" first="Evelyn" last="Despierre">Evelyn Despierre</name>
</author>
<author><name sortKey="Marth, Christian" sort="Marth, Christian" uniqKey="Marth C" first="Christian" last="Marth">Christian Marth</name>
</author>
<author><name sortKey="Hall, Marcia" sort="Hall, Marcia" uniqKey="Hall M" first="Marcia" last="Hall">Marcia Hall</name>
</author>
<author><name sortKey="Steer, Christopher B" sort="Steer, Christopher B" uniqKey="Steer C" first="Christopher B" last="Steer">Christopher B. Steer</name>
</author>
<author><name sortKey="Colombo, Nicoletta" sort="Colombo, Nicoletta" uniqKey="Colombo N" first="Nicoletta" last="Colombo">Nicoletta Colombo</name>
</author>
<author><name sortKey="Lesoin, Anne" sort="Lesoin, Anne" uniqKey="Lesoin A" first="Anne" last="Lesoin">Anne Lesoin</name>
</author>
<author><name sortKey="Casado, Antonio" sort="Casado, Antonio" uniqKey="Casado A" first="Antonio" last="Casado">Antonio Casado</name>
</author>
<author><name sortKey="Reinthaller, Alexander" sort="Reinthaller, Alexander" uniqKey="Reinthaller A" first="Alexander" last="Reinthaller">Alexander Reinthaller</name>
</author>
<author><name sortKey="Green, John" sort="Green, John" uniqKey="Green J" first="John" last="Green">John Green</name>
</author>
<author><name sortKey="Buck, Martin" sort="Buck, Martin" uniqKey="Buck M" first="Martin" last="Buck">Martin Buck</name>
</author>
<author><name sortKey="Ray Coquard, Isabelle" sort="Ray Coquard, Isabelle" uniqKey="Ray Coquard I" first="Isabelle" last="Ray-Coquard">Isabelle Ray-Coquard</name>
</author>
<author><name sortKey="Ferrero, Annamaria" sort="Ferrero, Annamaria" uniqKey="Ferrero A" first="Annamaria" last="Ferrero">Annamaria Ferrero</name>
</author>
<author><name sortKey="Favier, Laure" sort="Favier, Laure" uniqKey="Favier L" first="Laure" last="Favier">Laure Favier</name>
</author>
<author><name sortKey="Reed, Nick Simon" sort="Reed, Nick Simon" uniqKey="Reed N" first="Nick Simon" last="Reed">Nick Simon Reed</name>
</author>
<author><name sortKey="Cure, Herve" sort="Cure, Herve" uniqKey="Cure H" first="Hervé" last="Curé">Hervé Curé</name>
</author>
<author><name sortKey="Pujade Lauraine, Eric" sort="Pujade Lauraine, Eric" uniqKey="Pujade Lauraine E" first="Eric" last="Pujade-Lauraine">Eric Pujade-Lauraine</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2014">2014</date>
<idno type="RBID">pubmed:24366937</idno>
<idno type="pmid">24366937</idno>
<idno type="doi">10.1200/JCO.2013.50.5669</idno>
<idno type="wicri:Area/PubMed/Corpus">003941</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003941</idno>
<idno type="wicri:Area/PubMed/Curation">003826</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003826</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003826</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003826</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study.</title>
<author><name sortKey="Vergote, Ignace B" sort="Vergote, Ignace B" uniqKey="Vergote I" first="Ignace B" last="Vergote">Ignace B. Vergote</name>
<affiliation wicri:level="3"><nlm:affiliation>Ignace B. Vergote and Evelyn Despierre, University Hospitals Leuven and Katholieke Universiteit Leuven, Leuven; Corneel Coens, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Antonio Jimeno, University of Colorado School of Medicine, Aurora, CO; Florence Joly, Centre François Baclesse Caen, Caen; Anne Lesoin, Centre Oscar Lambret, Lille; Isabelle Ray-Coquard, Centre Léon Bérard, Lyon; Laure Favier, Centre Georges François Leclerc, Dijon; Hervé Curé, Unicancer Institut Jean Godinot, Reims; Eric Pujade-Lauraine, Hôpital Hôtel-Dieu, Paris, France; Dionyssios Katsaros, University of Turin; Annamaria Ferrero, Ospedale Mauriziano Umberto I, Turin; Nicoletta Colombo, University of Milan-Bicocca and Istituto Europeo di Oncologia, Milan, Italy; Christian Marth, Medical University of Innsbruck, Innsbruck; Alexander Reinthaller, Medical University of Vienna, Vienna, Austria; Marcia Hall, Mount Vernon Cancer Centre, Middlesex; John Green, University of Liverpool, Liverpool; Nick Simon Reed, Gartnavel General Hospitals, Glasgow, United Kingdom; Christopher B. Steer, Border Medical Oncology, Wodonga; Martin Buck, Government of Western Australia, Department of Health, Perth, Australia; and Antonio Casado, Universitario San Carlos, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Ignace B. Vergote and Evelyn Despierre, University Hospitals Leuven and Katholieke Universiteit Leuven, Leuven; Corneel Coens, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Antonio Jimeno, University of Colorado School of Medicine, Aurora, CO; Florence Joly, Centre François Baclesse Caen, Caen; Anne Lesoin, Centre Oscar Lambret, Lille; Isabelle Ray-Coquard, Centre Léon Bérard, Lyon; Laure Favier, Centre Georges François Leclerc, Dijon; Hervé Curé, Unicancer Institut Jean Godinot, Reims; Eric Pujade-Lauraine, Hôpital Hôtel-Dieu, Paris, France; Dionyssios Katsaros, University of Turin; Annamaria Ferrero, Ospedale Mauriziano Umberto I, Turin; Nicoletta Colombo, University of Milan-Bicocca and Istituto Europeo di Oncologia, Milan, Italy; Christian Marth, Medical University of Innsbruck, Innsbruck; Alexander Reinthaller, Medical University of Vienna, Vienna, Austria; Marcia Hall, Mount Vernon Cancer Centre, Middlesex; John Green, University of Liverpool, Liverpool; Nick Simon Reed, Gartnavel General Hospitals, Glasgow, United Kingdom; Christopher B. Steer, Border Medical Oncology, Wodonga; Martin Buck, Government of Western Australia, Department of Health, Perth, Australia; and Antonio Casado, Universitario San Carlos, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jimeno, Antonio" sort="Jimeno, Antonio" uniqKey="Jimeno A" first="Antonio" last="Jimeno">Antonio Jimeno</name>
</author>
<author><name sortKey="Joly, Florence" sort="Joly, Florence" uniqKey="Joly F" first="Florence" last="Joly">Florence Joly</name>
</author>
<author><name sortKey="Katsaros, Dionyssios" sort="Katsaros, Dionyssios" uniqKey="Katsaros D" first="Dionyssios" last="Katsaros">Dionyssios Katsaros</name>
</author>
<author><name sortKey="Coens, Corneel" sort="Coens, Corneel" uniqKey="Coens C" first="Corneel" last="Coens">Corneel Coens</name>
</author>
<author><name sortKey="Despierre, Evelyn" sort="Despierre, Evelyn" uniqKey="Despierre E" first="Evelyn" last="Despierre">Evelyn Despierre</name>
</author>
<author><name sortKey="Marth, Christian" sort="Marth, Christian" uniqKey="Marth C" first="Christian" last="Marth">Christian Marth</name>
</author>
<author><name sortKey="Hall, Marcia" sort="Hall, Marcia" uniqKey="Hall M" first="Marcia" last="Hall">Marcia Hall</name>
</author>
<author><name sortKey="Steer, Christopher B" sort="Steer, Christopher B" uniqKey="Steer C" first="Christopher B" last="Steer">Christopher B. Steer</name>
</author>
<author><name sortKey="Colombo, Nicoletta" sort="Colombo, Nicoletta" uniqKey="Colombo N" first="Nicoletta" last="Colombo">Nicoletta Colombo</name>
</author>
<author><name sortKey="Lesoin, Anne" sort="Lesoin, Anne" uniqKey="Lesoin A" first="Anne" last="Lesoin">Anne Lesoin</name>
</author>
<author><name sortKey="Casado, Antonio" sort="Casado, Antonio" uniqKey="Casado A" first="Antonio" last="Casado">Antonio Casado</name>
</author>
<author><name sortKey="Reinthaller, Alexander" sort="Reinthaller, Alexander" uniqKey="Reinthaller A" first="Alexander" last="Reinthaller">Alexander Reinthaller</name>
</author>
<author><name sortKey="Green, John" sort="Green, John" uniqKey="Green J" first="John" last="Green">John Green</name>
</author>
<author><name sortKey="Buck, Martin" sort="Buck, Martin" uniqKey="Buck M" first="Martin" last="Buck">Martin Buck</name>
</author>
<author><name sortKey="Ray Coquard, Isabelle" sort="Ray Coquard, Isabelle" uniqKey="Ray Coquard I" first="Isabelle" last="Ray-Coquard">Isabelle Ray-Coquard</name>
</author>
<author><name sortKey="Ferrero, Annamaria" sort="Ferrero, Annamaria" uniqKey="Ferrero A" first="Annamaria" last="Ferrero">Annamaria Ferrero</name>
</author>
<author><name sortKey="Favier, Laure" sort="Favier, Laure" uniqKey="Favier L" first="Laure" last="Favier">Laure Favier</name>
</author>
<author><name sortKey="Reed, Nick Simon" sort="Reed, Nick Simon" uniqKey="Reed N" first="Nick Simon" last="Reed">Nick Simon Reed</name>
</author>
<author><name sortKey="Cure, Herve" sort="Cure, Herve" uniqKey="Cure H" first="Hervé" last="Curé">Hervé Curé</name>
</author>
<author><name sortKey="Pujade Lauraine, Eric" sort="Pujade Lauraine, Eric" uniqKey="Pujade Lauraine E" first="Eric" last="Pujade-Lauraine">Eric Pujade-Lauraine</name>
</author>
</analytic>
<series><title level="j">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</title>
<idno type="eISSN">1527-7755</idno>
<imprint><date when="2014" type="published">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term>
<term>Disease-Free Survival</term>
<term>Drug Administration Schedule</term>
<term>Drug Eruptions (etiology)</term>
<term>Erlotinib Hydrochloride</term>
<term>Europe</term>
<term>Fallopian Tube Neoplasms (drug therapy)</term>
<term>Fallopian Tube Neoplasms (pathology)</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Immunohistochemistry</term>
<term>In Situ Hybridization, Fluorescence</term>
<term>Kaplan-Meier Estimate</term>
<term>Maintenance Chemotherapy</term>
<term>Middle Aged</term>
<term>Mutation</term>
<term>Neoplasm Staging</term>
<term>Neoplasms, Glandular and Epithelial (drug therapy)</term>
<term>Neoplasms, Glandular and Epithelial (pathology)</term>
<term>Ovarian Neoplasms (drug therapy)</term>
<term>Ovarian Neoplasms (pathology)</term>
<term>Peritoneal Neoplasms (drug therapy)</term>
<term>Peritoneal Neoplasms (pathology)</term>
<term>Platinum Compounds (administration & dosage)</term>
<term>Protein Kinase Inhibitors (administration & dosage)</term>
<term>Protein Kinase Inhibitors (adverse effects)</term>
<term>Quality of Life</term>
<term>Quinazolines (administration & dosage)</term>
<term>Quinazolines (adverse effects)</term>
<term>Receptor, Epidermal Growth Factor (genetics)</term>
<term>Signal Transduction (genetics)</term>
<term>Watchful Waiting</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Calendrier d'administration des médicaments</term>
<term>Chimiothérapie de maintenance</term>
<term>Chlorhydrate d'erlotinib</term>
<term>Composés du platine (administration et posologie)</term>
<term>Estimation de Kaplan-Meier</term>
<term>Europe</term>
<term>Femelle</term>
<term>Humains</term>
<term>Immunohistochimie</term>
<term>Inhibiteurs de protéines kinases (administration et posologie)</term>
<term>Inhibiteurs de protéines kinases (effets indésirables)</term>
<term>Mutation</term>
<term>Observation (surveillance clinique)</term>
<term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term>
<term>Qualité de vie</term>
<term>Quinazolines (administration et posologie)</term>
<term>Quinazolines (effets indésirables)</term>
<term>Récepteur du facteur de croissance épidermique (génétique)</term>
<term>Stade de la tumeur</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Survie sans rechute</term>
<term>Technique FISH</term>
<term>Toxidermies (étiologie)</term>
<term>Transduction du signal (génétique)</term>
<term>Tumeurs de l'ovaire (anatomopathologie)</term>
<term>Tumeurs de l'ovaire (traitement médicamenteux)</term>
<term>Tumeurs de la trompe de Fallope (anatomopathologie)</term>
<term>Tumeurs de la trompe de Fallope (traitement médicamenteux)</term>
<term>Tumeurs du péritoine (anatomopathologie)</term>
<term>Tumeurs du péritoine (traitement médicamenteux)</term>
<term>Tumeurs épithéliales épidermoïdes et glandulaires (anatomopathologie)</term>
<term>Tumeurs épithéliales épidermoïdes et glandulaires (traitement médicamenteux)</term>
<term>Études de suivi</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Platinum Compounds</term>
<term>Protein Kinase Inhibitors</term>
<term>Quinazolines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Protein Kinase Inhibitors</term>
<term>Quinazolines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Receptor, Epidermal Growth Factor</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Erlotinib Hydrochloride</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>Europe</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Composés du platine</term>
<term>Inhibiteurs de protéines kinases</term>
<term>Quinazolines</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Tumeurs de l'ovaire</term>
<term>Tumeurs de la trompe de Fallope</term>
<term>Tumeurs du péritoine</term>
<term>Tumeurs épithéliales épidermoïdes et glandulaires</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Fallopian Tube Neoplasms</term>
<term>Neoplasms, Glandular and Epithelial</term>
<term>Ovarian Neoplasms</term>
<term>Peritoneal Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Inhibiteurs de protéines kinases</term>
<term>Quinazolines</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Drug Eruptions</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Signal Transduction</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Récepteur du facteur de croissance épidermique</term>
<term>Transduction du signal</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Fallopian Tube Neoplasms</term>
<term>Neoplasms, Glandular and Epithelial</term>
<term>Ovarian Neoplasms</term>
<term>Peritoneal Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs de l'ovaire</term>
<term>Tumeurs de la trompe de Fallope</term>
<term>Tumeurs du péritoine</term>
<term>Tumeurs épithéliales épidermoïdes et glandulaires</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Protocoles de polychimiothérapie antinéoplasique</term>
</keywords>
<keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Toxidermies</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Disease-Free Survival</term>
<term>Drug Administration Schedule</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Immunohistochemistry</term>
<term>In Situ Hybridization, Fluorescence</term>
<term>Kaplan-Meier Estimate</term>
<term>Maintenance Chemotherapy</term>
<term>Middle Aged</term>
<term>Mutation</term>
<term>Neoplasm Staging</term>
<term>Quality of Life</term>
<term>Watchful Waiting</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Calendrier d'administration des médicaments</term>
<term>Chimiothérapie de maintenance</term>
<term>Chlorhydrate d'erlotinib</term>
<term>Estimation de Kaplan-Meier</term>
<term>Europe</term>
<term>Femelle</term>
<term>Humains</term>
<term>Immunohistochimie</term>
<term>Mutation</term>
<term>Observation (surveillance clinique)</term>
<term>Qualité de vie</term>
<term>Stade de la tumeur</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Survie sans rechute</term>
<term>Technique FISH</term>
<term>Études de suivi</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">This trial evaluated the efficacy of maintenance erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, after first-line chemotherapy.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24366937</PMID>
<DateCreated><Year>2014</Year>
<Month>01</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted><Year>2014</Year>
<Month>03</Month>
<Day>21</Day>
</DateCompleted>
<DateRevised><Year>2015</Year>
<Month>11</Month>
<Day>19</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1527-7755</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>32</Volume>
<Issue>4</Issue>
<PubDate><Year>2014</Year>
<Month>Feb</Month>
<Day>01</Day>
</PubDate>
</JournalIssue>
<Title>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</Title>
<ISOAbbreviation>J. Clin. Oncol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study.</ArticleTitle>
<Pagination><MedlinePgn>320-6</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1200/JCO.2013.50.5669</ELocationID>
<Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">This trial evaluated the efficacy of maintenance erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, after first-line chemotherapy.</AbstractText>
<AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Eligible patients had high-risk International Federation of Gynecology and Obstetrics stage I or stage II to IV epithelial ovarian, primary peritoneal, or fallopian tube cancer and were not selected for EGFR expression. All patients underwent first-line platinum-based chemotherapy (CT) and showed no signs of progression at the end of CT. Patients were randomly assigned to maintenance erlotinib 150 mg orally daily for 2 years or to observation. EGFR immunohistochemistry (IHC), fluorescent in situ hybridization (FISH), and mutation analyses were performed in 318 patients.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Between October 2005 and February 2008, 835 patients were randomly assigned (median follow-up, 51 months). Twenty-six percent of the patients stopped erlotinib as a result of adverse effects (of these, 67% were due to rash). For erlotinib and observation, respectively, the median progression-free survival was 12.7 and 12.4 months (hazard ratio [HR], 1.05; 95% CI, 0.90 to 1.23), and the median overall survival was 50.8 and 59.1 months (HR, 0.99; 95% CI, 0.81 to 1.20 months), respectively. No subgroup could be identified with improved effect of erlotinib, based on IHC or FISH for EGFR, or mutations in genes related to the EGFR pathway, or on rash during erlotinib therapy. However, patients with a positive FISH EGFR score had a worse overall survival (46.1 months) than those with a negative score (67.0 months; HR, 1.56; 95% CI, 1.01 to 2.40; P = .044). Global health/quality-of-life scores showed a significant difference during the first year (P = .0102) in favor of the observation arm.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Maintenance erlotinib after first-line treatment in ovarian cancer did not improve progression-free or overall survival.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vergote</LastName>
<ForeName>Ignace B</ForeName>
<Initials>IB</Initials>
<AffiliationInfo><Affiliation>Ignace B. Vergote and Evelyn Despierre, University Hospitals Leuven and Katholieke Universiteit Leuven, Leuven; Corneel Coens, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Antonio Jimeno, University of Colorado School of Medicine, Aurora, CO; Florence Joly, Centre François Baclesse Caen, Caen; Anne Lesoin, Centre Oscar Lambret, Lille; Isabelle Ray-Coquard, Centre Léon Bérard, Lyon; Laure Favier, Centre Georges François Leclerc, Dijon; Hervé Curé, Unicancer Institut Jean Godinot, Reims; Eric Pujade-Lauraine, Hôpital Hôtel-Dieu, Paris, France; Dionyssios Katsaros, University of Turin; Annamaria Ferrero, Ospedale Mauriziano Umberto I, Turin; Nicoletta Colombo, University of Milan-Bicocca and Istituto Europeo di Oncologia, Milan, Italy; Christian Marth, Medical University of Innsbruck, Innsbruck; Alexander Reinthaller, Medical University of Vienna, Vienna, Austria; Marcia Hall, Mount Vernon Cancer Centre, Middlesex; John Green, University of Liverpool, Liverpool; Nick Simon Reed, Gartnavel General Hospitals, Glasgow, United Kingdom; Christopher B. Steer, Border Medical Oncology, Wodonga; Martin Buck, Government of Western Australia, Department of Health, Perth, Australia; and Antonio Casado, Universitario San Carlos, Madrid, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Jimeno</LastName>
<ForeName>Antonio</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y"><LastName>Joly</LastName>
<ForeName>Florence</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y"><LastName>Katsaros</LastName>
<ForeName>Dionyssios</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y"><LastName>Coens</LastName>
<ForeName>Corneel</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y"><LastName>Despierre</LastName>
<ForeName>Evelyn</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y"><LastName>Marth</LastName>
<ForeName>Christian</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y"><LastName>Hall</LastName>
<ForeName>Marcia</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Steer</LastName>
<ForeName>Christopher B</ForeName>
<Initials>CB</Initials>
</Author>
<Author ValidYN="Y"><LastName>Colombo</LastName>
<ForeName>Nicoletta</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y"><LastName>Lesoin</LastName>
<ForeName>Anne</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y"><LastName>Casado</LastName>
<ForeName>Antonio</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y"><LastName>Reinthaller</LastName>
<ForeName>Alexander</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y"><LastName>Green</LastName>
<ForeName>John</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><LastName>Buck</LastName>
<ForeName>Martin</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Ray-Coquard</LastName>
<ForeName>Isabelle</ForeName>
<Initials>I</Initials>
</Author>
<Author ValidYN="Y"><LastName>Ferrero</LastName>
<ForeName>Annamaria</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y"><LastName>Favier</LastName>
<ForeName>Laure</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y"><LastName>Reed</LastName>
<ForeName>Nick Simon</ForeName>
<Initials>NS</Initials>
</Author>
<Author ValidYN="Y"><LastName>Curé</LastName>
<ForeName>Hervé</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y"><LastName>Pujade-Lauraine</LastName>
<ForeName>Eric</ForeName>
<Initials>E</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName>
<AccessionNumberList><AccessionNumber>NCT00263822</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016448">Multicenter Study</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2013</Year>
<Month>12</Month>
<Day>23</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>J Clin Oncol</MedlineTA>
<NlmUniqueID>8309333</NlmUniqueID>
<ISSNLinking>0732-183X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017671">Platinum Compounds</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011799">Quinazolines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>DA87705X9K</RegistryNumber>
<NameOfSubstance UI="D000069347">Erlotinib Hydrochloride</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="C512478">EGFR protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D011958">Receptor, Epidermal Growth Factor</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Disease" UI="C538090">Ovarian epithelial cancer</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Clin Oncol. 2014 Aug 1;32(22):2388</RefSource>
<PMID Version="1">24982455</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn"><RefSource>J Clin Oncol. 2014 Aug 1;32(22):2387-8</RefSource>
<PMID Version="1">24982465</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003875" MajorTopicYN="N">Drug Eruptions</DescriptorName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000069347" MajorTopicYN="N">Erlotinib Hydrochloride</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N" Type="Geographic">Europe</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005185" MajorTopicYN="N">Fallopian Tube Neoplasms</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017404" MajorTopicYN="N">In Situ Hybridization, Fluorescence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D060046" MajorTopicYN="N">Maintenance Chemotherapy</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009375" MajorTopicYN="N">Neoplasms, Glandular and Epithelial</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010051" MajorTopicYN="N">Ovarian Neoplasms</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010534" MajorTopicYN="N">Peritoneal Neoplasms</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017671" MajorTopicYN="N">Platinum Compounds</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011799" MajorTopicYN="N">Quinazolines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011958" MajorTopicYN="N">Receptor, Epidermal Growth Factor</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D057832" MajorTopicYN="N">Watchful Waiting</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year>
<Month>12</Month>
<Day>25</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2013</Year>
<Month>12</Month>
<Day>25</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2014</Year>
<Month>3</Month>
<Day>22</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">24366937</ArticleId>
<ArticleId IdType="pii">JCO.2013.50.5669</ArticleId>
<ArticleId IdType="doi">10.1200/JCO.2013.50.5669</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Espagne</li>
</country>
<region><li>Communauté de Madrid</li>
</region>
<settlement><li>Madrid</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Buck, Martin" sort="Buck, Martin" uniqKey="Buck M" first="Martin" last="Buck">Martin Buck</name>
<name sortKey="Casado, Antonio" sort="Casado, Antonio" uniqKey="Casado A" first="Antonio" last="Casado">Antonio Casado</name>
<name sortKey="Coens, Corneel" sort="Coens, Corneel" uniqKey="Coens C" first="Corneel" last="Coens">Corneel Coens</name>
<name sortKey="Colombo, Nicoletta" sort="Colombo, Nicoletta" uniqKey="Colombo N" first="Nicoletta" last="Colombo">Nicoletta Colombo</name>
<name sortKey="Cure, Herve" sort="Cure, Herve" uniqKey="Cure H" first="Hervé" last="Curé">Hervé Curé</name>
<name sortKey="Despierre, Evelyn" sort="Despierre, Evelyn" uniqKey="Despierre E" first="Evelyn" last="Despierre">Evelyn Despierre</name>
<name sortKey="Favier, Laure" sort="Favier, Laure" uniqKey="Favier L" first="Laure" last="Favier">Laure Favier</name>
<name sortKey="Ferrero, Annamaria" sort="Ferrero, Annamaria" uniqKey="Ferrero A" first="Annamaria" last="Ferrero">Annamaria Ferrero</name>
<name sortKey="Green, John" sort="Green, John" uniqKey="Green J" first="John" last="Green">John Green</name>
<name sortKey="Hall, Marcia" sort="Hall, Marcia" uniqKey="Hall M" first="Marcia" last="Hall">Marcia Hall</name>
<name sortKey="Jimeno, Antonio" sort="Jimeno, Antonio" uniqKey="Jimeno A" first="Antonio" last="Jimeno">Antonio Jimeno</name>
<name sortKey="Joly, Florence" sort="Joly, Florence" uniqKey="Joly F" first="Florence" last="Joly">Florence Joly</name>
<name sortKey="Katsaros, Dionyssios" sort="Katsaros, Dionyssios" uniqKey="Katsaros D" first="Dionyssios" last="Katsaros">Dionyssios Katsaros</name>
<name sortKey="Lesoin, Anne" sort="Lesoin, Anne" uniqKey="Lesoin A" first="Anne" last="Lesoin">Anne Lesoin</name>
<name sortKey="Marth, Christian" sort="Marth, Christian" uniqKey="Marth C" first="Christian" last="Marth">Christian Marth</name>
<name sortKey="Pujade Lauraine, Eric" sort="Pujade Lauraine, Eric" uniqKey="Pujade Lauraine E" first="Eric" last="Pujade-Lauraine">Eric Pujade-Lauraine</name>
<name sortKey="Ray Coquard, Isabelle" sort="Ray Coquard, Isabelle" uniqKey="Ray Coquard I" first="Isabelle" last="Ray-Coquard">Isabelle Ray-Coquard</name>
<name sortKey="Reed, Nick Simon" sort="Reed, Nick Simon" uniqKey="Reed N" first="Nick Simon" last="Reed">Nick Simon Reed</name>
<name sortKey="Reinthaller, Alexander" sort="Reinthaller, Alexander" uniqKey="Reinthaller A" first="Alexander" last="Reinthaller">Alexander Reinthaller</name>
<name sortKey="Steer, Christopher B" sort="Steer, Christopher B" uniqKey="Steer C" first="Christopher B" last="Steer">Christopher B. Steer</name>
</noCountry>
<country name="Espagne"><region name="Communauté de Madrid"><name sortKey="Vergote, Ignace B" sort="Vergote, Ignace B" uniqKey="Vergote I" first="Ignace B" last="Vergote">Ignace B. Vergote</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003254 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 003254 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:24366937
   |texte=   Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:24366937" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a AustralieFrV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie